ENTX (Entera Bio Ltd. Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by ENTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Haya Taitel | Director | A | — | — |
| 2026-08-07 | Miranda Jayne Toledano | Chief Executive Officer | A | — | — |
| 2026-08-07 | Gregory Burshtein | Chief of R&D | A | — | — |
| 2026-08-07 | Steven D Rubin | Director | A | — | — |
| 2026-08-07 | Sean Ellis | Director | A | — | — |
| 2026-08-07 | Geno J Germano | Director | A | — | — |
| 2026-08-07 | Dana Yaacov-Garbeli | Chief Financial Officer | A | — | — |
| 2026-08-07 | Hillel Galitzer | Chief Operating Officer | A | — | — |
| 2026-08-07 | Yonatan Malca | Director | A | — | — |
| 2026-08-07 | Miranda Jayne Toledano | Chief Executive Officer | A | — | — |
| 2026-08-07 | Steven D Rubin | Director | A | — | — |
| 2026-08-07 | Haya Taitel | Director | A | — | — |
| 2026-08-07 | Hillel Galitzer | Chief Operating Officer | A | — | — |
| 2026-08-07 | Yonatan Malca | Director | A | — | — |
| 2026-08-07 | Dana Yaacov-Garbeli | Chief Financial Officer | A | — | — |
| 2026-08-07 | Geno J Germano | Director | A | — | — |
| 2026-08-07 | Sean Ellis | Director | A | — | — |
| 2026-08-07 | Gregory Burshtein | Chief of R&D | A | — | — |
| 2026-07-16 | Miranda Jayne Toledano | Chief Executive Officer | A | — | — |
| 2026-05-08 | Dana Yaacov-Garbeli | Chief Financial Officer | A | — | — |
| 2026-05-08 | Gregory Burshtein | Chief of R&D | A | — | — |
| 2026-05-08 | Hillel Galitzer | Chief Operating Officer | A | — | — |
| 2026-03-11 | Geno J Germano | Director | Buy | — | — |
| 2026-03-09 | Sean Ellis | Director | Buy | — | — |
| 2026-02-17 | Steven D Rubin | Director | Buy | — | — |
| 2026-02-11 | Geno J Germano | Director | Buy | — | — |
| 2026-02-11 | Sean Ellis | Director | Buy | — | — |
| 2026-02-11 | Haya Taitel | Director | Buy | — | — |
| 2026-02-11 | Steven D Rubin | Director | Buy | — | — |
| 2026-01-02 | Sean Ellis | Director | A | — | — |
| 2026-01-02 | GERALD M OSTROV | Director | A | — | — |
| 2026-01-02 | Haya Taitel | Director | A | — | — |
| 2026-01-02 | Yonatan Malca | Director | A | — | — |
| 2026-01-02 | GERALD M LIEBERMAN | Director | A | — | — |
| 2025-12-30 | Miranda Jayne Toledano | Chief Executive Officer | Buy | — | — |
| 2025-07-18 | Dana Yaacov-Garbeli | Chief Financial Officer | A | — | — |
| 2025-07-18 | Gregory Burshtein | Chief of R&D | A | — | — |
| 2025-07-18 | Miranda Jayne Toledano | Chief Executive Officer | A | — | — |
| 2025-04-30 | Hillel Galitzer | Chief Operating Officer | A | — | — |
| 2025-04-03 | GERALD M LIEBERMAN | Director | M | — | — |
| 2025-01-17 | Sean Ellis | Director | A | — | — |
| 2025-01-17 | Yonatan Malca | Director | A | — | — |
| 2025-01-17 | Haya Taitel | Director | A | — | — |
| 2025-01-17 | GERALD M OSTROV | Director | A | — | — |
| 2025-01-17 | GERALD M LIEBERMAN | Director | A | — | — |
| 2024-10-04 | Haya Taitel | Director | A | — | — |
| 2024-10-04 | GERALD M OSTROV | Director | A | — | — |
| 2024-10-04 | Sean Ellis | Director | A | — | — |
| 2024-10-04 | Yonatan Malca | Director | A | — | — |
| 2024-10-04 | GERALD M LIEBERMAN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 774,142 | — |
| — | Director | 344,654 | — |
| — | Chief Financial Officer | 258,172 | — |
| — | Director | 208,132 | — |
| — | Chief of R&D | 189,033 | — |
| — | Chief Operating Officer | 163,566 | — |
| — | Director | 119,269 | — |
| — | Director | 100,231 | — |
| — | Director | 75,657 | — |
| — | Director | 65,014 | — |
| — | Director | 34,117 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ENTX quote page; the site-wide leaderboard is on the insider transactions hub.